A cooperation agreement was signed between Eva Pharma Pharmaceutical Industries and Eli Lilly International Pharmaceutical Company to localize the production of biological drugs for the treatment of diabetes in Egypt.
The agreement aims to maintain the supply of insulin to low- and middle-income countries.
Major General Dr. Bahaa El-Din Zidan, Chairman of the Board of Directors of the Egyptian Uniform Procurement and Medical Supplies Authority, said the agreement came within the framework of President Abdel Fattah El-Sisi’s directives to localize the medical industry, encourage investment and increase exports, noting that the Egyptian Uniform Procurement Authority plays an important role in attracting investment in the medical sector.
Zidane added on the sidelines of the signing of the agreement that the Egyptian Unified Purchasing Authority had agreed with the pharmaceutical company Eva Pharma to conclude a cooperation agreement with the international pharmaceutical company Eli Lilly to localize the production of biologics for diabetes in Egypt and ensure the supply of insulin to countries with low and middle income.
In this regard, Dr. Ali Uf, head of the Medicines Division of the Chamber of Commerce, said that there is a general trend that the president is pushing for, namely the localization of vital and important industries within Egypt so that self-sufficiency arises. in addition to exporting what exceeds our domestic needs, in order to create economic growth and provide hard currency, especially in the field of the pharmaceutical industry in general, because the drug sector is number one worldwide and this is what the Corona pandemic has led to . proven.
Auf added that countries that did not have a medical infrastructure suffered severe crises in light of the outbreak of this pandemic, but Egypt survived this crisis because it has a well-functioning medical sector, noting that the overall strategy of the state is to to provide medicines that we import to save currency, not outside control of Egyptian medicine.
He pointed out that Egypt covers 92% of the Egyptians’ needs for drugs, but there are 8% of biological drugs, and their production in Egypt requires high technology and high costs, including insulin, so the state is working to localize its industry, pointing out that 10% of the Egyptian population suffers from diabetes, so it’s a modern disease.
Source: Country Echo